tirzepatide mash fda Key milestones of in the treatment of diabetes, obesity and FDA approved Madrigal's Resmetirom (Rezdiffra®)

Breaking down the numbers further: 5% weight loss achieved : 95% with tirzepatide vs 79% with semaglutide 10% weight loss achieved : 89% with tirzepatide vs 61% with semaglutide 15% weight loss achieved : 77% with tirzepatide vs 39% with semaglutide 20% weight loss achieved : 62% with tirzepatide vs 23% with semaglutide Diabetes Management For patients with type 2 diabetes, both medications offer significant benefits, though tirzepatide shows a slight edge: HbA1c reduction : Tirzepatide typically lowers HbA1c by 2-2.5%, while semaglutide achieves 1-2% reduction Fasting glucose improvement : Both medications effectively lower fasting blood sugar Time in range : Patients on both medications spend more time with blood sugars in the target range Insulin sensitivity : Tirzepatide may provide greater improvements in insulin sensitivity Cardiovascular Benefits Semaglutide has established cardiovascular benefits with FDA approval for reducing heart attack, stroke, and cardiovascular death risk in patients with type 2 diabetes or obesity with established heart disease

Topical Peptides: Comparing Side Effects When administering peptides, the choice between injectable and topical forms can significantly impact results and safety

Despite the numerous benefits, clinicians must be careful while prescribing semaglutide because each brand has different preparations and variable dosage schemes linked to different benefits and side effects

Week 2: Inject on Wednesday